In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed® 508 insulin pump

Diabetes Technology and Therapeutics

Volumn 9, Issue 1, 2007, Pages 75-79

  Senstius, J ^a   Harboe, E ^a   Westermann, H ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; META CRESOL; PHENOL;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; INSULIN INFUSION; INSULIN PUMP; PRECIPITATION; PRIORITY JOURNAL; TEMPERATURE; VIBRATION;

DRUG STABILITY; HYDROGEN-ION CONCENTRATION; INSULIN; INSULIN INFUSION SYSTEMS; MOTION; PRESERVATIVES, PHARMACEUTICAL; TEMPERATURE;

EID: 33847184241     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.0041     Document Type: Article

References (14)

1. Torrance T, Franklin V, Greene S: Insulin pumps. A growing option in the UK for children and young adults with type 1 diabetes. Arch Dis Child 2003;88:949-953.
2. Lenhard MJ, Reeves GD: Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-2300.
3. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002;25:439-444.
4. Bode BW, Tamborlane WV, Davidson PC: Insulin pump therapy in the 21st Century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 2002;111:69-77; quiz 27.
5. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18(Suppl 1):S14-S20.
6. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-1167.
7. Jars MU, Hvass A, Waaben D: Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions. Pharm Res 2002;19:621-628.
8. Bode BW, Strange P: Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
9. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603.
10. Walter HM, Timmler R, Mehnert H: Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion. Diabetes Res 1990;13:75-77.
11. U.S. Food and Drug Administration Draft Guidance: Requirements Proposed for Pump Insulins and Insulin Pumps. Rockville, MD: U.S. Food and Drug Administration, 1985.
12. Committee for Proprietary Medicinal Products: Note for Guidance on In-Use Stability Testing of Human Medicinal Products. March 1, 2001. http://www.EMEA.eu.int/pdfs/human/qwp/293499en.pdf (accessed October 1, 2006).
13. Brange J, Langkjaer L: Insulin structure and stability. Pharm Biotechnol 1993;5:315-350.
14. Brange J: Stability of Insulin. Studies on the Physical and Chemical Stability of Insulin in Pharmaceutical Formulation. Boston: Kluwer Academic Publishers, 1994.